肺癌
小RNA
细胞外小泡
分子生物学
化学
荧光计
液体活检
癌症研究
核酸
计算生物学
癌症生物标志物
荧光素酶
胞外囊泡
生物
滚动圆复制
细胞生物学
癌细胞
癌症
细胞外
实时聚合酶链反应
分析灵敏度
灵敏度(控制系统)
作者
Jing Hou,Yuan Jiang,Mengqian Cong,Zhiqin Li,Ying He,Tingting Jia,Xinxin Lu,Weixing Zhao,Wanjing Guo,Zirui Li,Lei Jiang,Jun Jiang
标识
DOI:10.1016/j.snr.2026.100451
摘要
• A one-pot exponential amplification platform based on the combination of CRISPR - Cas12a and RCA • Ultra-high sensitivity (LOD: 8 fM) and specificity were demonstrated for miRNA detection • The platform can distinguish single-nucleotide variants of homologous miRNAs • A smartphone-driven point-of-care testing system was constructed for portable diagnostics The clinical translation of microRNAs as cancer biomarkers is challenging due to the lack of detection assays that are simple, rapid, and sensitive enough for point-of-care use. Here, we present a one-pot, isothermal CRISPR-Cas12a platform for miRNA detection that integrates rolling circle amplification (RCA) with the CRISPR-Cas12a system for the direct detection of miRNAs. Our assay uniquely leverages the cis-cleavage activity of Cas12a to fragment RCA amplicons, enabling an exponential amplification cycle, while simultaneously employing its trans-cleavage activity for real-time fluorescent signal readout. This true one-step reaction does not require separate pre-amplifications. When applied to plasma-derived extracellular vesicles, the assay detected the lung cancer-associated miRNA miR-451a at a sensitivity of 8 fM with single-nucleotide specificity. The assay is rapid, and its compatibility with a smartphone-based fluorimeter demonstrates its potential for point-of-care testing. In a clinical validation study using over 100 plasma samples, the assay distinguished lung cancer patients from healthy controls with an area under the curve (AUC) of 0.90. The 451a-CRISPR platform represents a significant advancement towards a simple and effective liquid biopsy tool for early cancer detection. This publication does not involve research data.
科研通智能强力驱动
Strongly Powered by AbleSci AI